KRAS and colorectal carcinoma: In the phase I part of CodeBreaK 100, 42 patients with advanced KRAS G12C mutated CRC were treated with sotorasib monotherapy, and ORR was 7.1% (3 patients) and mPFS was 4.0 months [8].